

## Paradigm Biopharma Melbourne Investor Lunch Briefing

---

**Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”)**, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce details for an investor lunch briefing to be held in Melbourne on Wednesday, 23 September 2026.

As part of the session, Paradigm’s senior management team will provide a Company presentation and update on the development of Zilosul® (injectable pentosan polysulfate sodium) for the treatment of knee osteoarthritis, including progress across the Company’s Phase 3 clinical program and broader corporate and commercial activities.

Investors will also have the opportunity to engage directly with senior management and ask questions throughout the lunch.

### Event Details

**Date:** Wednesday, 23 September 2026

**Time:** 12:00pm – 2:00pm

**Location:** The Observatory  
Garden State Hotel  
101 Flinders Lane  
Melbourne VIC 3000

**Dress:** Business or smart casual

**RSVP:** Places are strictly limited, with existing Paradigm shareholders to be given priority in the allocation of available places.

Please RSVP by 5:00pm AEST, Friday, 11 September 2026 to:

**Simon White**

[investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)

Please include your name and confirm if you are a Paradigm shareholder when responding. Please also advise of any dietary requirements.

Attendance will be confirmed by return email following receipt of your RSVP.

The Paradigm team looks forward to meeting investors who can join us on the day.

### About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for

the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd.

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)